



Lekha Mikkilineni

Assistant Professor of Medicine (Blood and Marrow Transplantation & Cellular Therapy)

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICE (PRIMARY)

- **Tumor Genomics Precision Oncology Practice**

900 Blake Wilbur, 2nd Flr

Stanford, CA 94305

Tel (650) 498-6000 Fax (650) 725-3321

Bio

BIO

Dr. Lekha Mikkilineni is a board-certified medical oncologist. She is also an Assistant Professor in the Department of Medicine, Division of Blood & Marrow Transplant and Cellular Therapy.

Dr. Mikkilineni has extensive experience treating blood and bone marrow cancers. She currently provides care through the Bone Marrow Transplant & Cellular Therapy Program at Stanford Health Care. Her clinical focus is multiple myeloma, plasma-cell leukemia, Extramedullary myeloma, high-risk myeloma, CAR T cell therapy, bispecific therapy, amyloidosis, POEMS syndrome, and Waldenstrom's macroglobunemia.

Dr. Mikkilineni's research centers on exploring novel CAR T-cell therapies to treat multiple myeloma and to define mechanisms of resistance to immunotherapy. She is particularly focused on understanding how to improve therapies for multiple myeloma patients who have extramedullary disease or high-risk features. Prior to coming to Stanford, she ran phase 1 CAR T-cell trials for multiple myeloma targeting BCMA and SLAMF7 at the National Cancer Institute.

Dr. Mikkilineni received the Conquer Cancer Foundation Young Investigator Award from the American Society of Clinical Oncology for her research focusing on SLAMF7 as a potential target for multiple myeloma. She has received honors and awards for her work at the NCI. She has completed fellowships in hematology/oncology and immunotherapy at the National Heart, Lung, and Blood Institute/National Cancer Institute. She finished her residency in internal medicine at Thomas Jefferson University Hospital. She holds a Master of Science in medical sciences from Boston University and a medical degree from Tulane University.

Dr. Mikkilineni has authored book chapters and published research in numerous high-impact academic journals. She has presented her findings through oral and poster presentations at national and international conferences.

CLINICAL FOCUS

- Medical Oncology

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Blood & Marrow Transplantation

PROFESSIONAL EDUCATION

- Medical Education: Tulane University School of Medicine (2013) LA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2020)
- Fellowship: National Cancer Institute - Center Cancer Research (2019) MD
- Board Certification: Internal Medicine, American Board of Internal Medicine (2017)
- Residency: Thomas Jefferson University Hospital Internal Medicine Residency (2016) PA

Research & Scholarship

CLINICAL TRIALS

- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Recruiting
- A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucl Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma, Not Recruiting
- A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM), Not Specified

Publications

PUBLICATIONS

- **Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.** *Blood cancer journal*
Pasvolsky, O., Dima, D., Feng, L., Dong, W., Richards, T., Davis, J. A., Afrough, A., Vazquez-Martinez, M., Sannareddy, A., Goel, U., Banerjee, R., Khouri, J., Cervoni, et al
2025; 15 (1): 92
- **Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.** *Blood advances*
Banerjee, R., Richards, A., Midha, S., Afrough, A., Anwer, F., Atanackovic, D., Atrash, S., Bachanova, V., Beitinjaneh, A. M., Ouchveridze, E., Castaneda Puglianini, O., Chhabra, S., Cicero, et al
2025
- **Comparison of Standard-of-Care Idecabtagene Vicleucl and Ciltacabtagene Autoleucl in Relapsed/Refractory Multiple Myeloma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Hansen, D. K., Peres, L. C., Dima, D., Richards, A., Shune, L., Afrough, A., Midha, S., Dhakal, B., Kocoglu, M. H., Atrash, S., Ferreri, C., Castaneda, O., Davis, et al
2025: JCO2401730
- **CAR T-cell therapy to treat multiple myeloma: current state and future directions.** *Cancer metastasis reviews*
Reddy, S. T., Hosoya, H., Mikkilineni, L.
2024; 44 (1): 14
- **A 17-Year Experience of a Large Dedicated Fellowship in Blood and Marrow Transplantation and Cellular Therapy: A Blueprint for Modern Day Training Program.** *Journal of cancer education : the official journal of the American Association for Cancer Education*
Bharadwaj, S., Lowsky, R., Mikkilineni, L., Smith, M., Weng, W. K.
2024
- **Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucl Therapy for Relapsed/Refractory Multiple Myeloma**
Hosoya, H., Fernandez-Pol, S., Gubatan, J., Ehlinger, Z., Lohman, C., Torres, A., Najidh, S., Kwang, A., Duran, G., Wright, C., Kennedy, V. E., Bharadwaj, S., Smith, et al
ELSEVIER.2024: 4846-4847

- **CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up**
Kramer, A., Baird, J. H., Srinagesh, H., Egeler, E., Levine, K., Brown, A. K., Mavroukakis, S., Cunanan, K., Su, Y., Agarwal, N., Hamilton, M. P., Bharadwaj, S., Arai, et al
ELSEVIER.2024: 70-71
- **Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms**
Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A., Srinagesh, H., Good, Z., Kang, X., Olsen, M., Liu, C., Tian, F., Sworder, B. J., Hosoya, et al
ELSEVIER.2024: 96-97
- **Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma.** *Blood cancer journal*
Fortuna, G. G., Banerjee, R., Savid-Frontera, C., Song, J., Morán-Segura, C. M., Nguyen, J. V., Lekakis, L., Fernandez-Pol, S., Samraj, A. N., Naresh, K. N., Vazquez-Martinez, M., Baz, R. C., Spiegel, et al
2024; 14 (1): 180
- **Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucler for Relapsed/Refractory Multiple Myeloma.** *Blood*
Sidana, S., Patel, K. K., Peres, L. C., Bansal, R., Kocoglu, M. H., Shune, L., Atrash, S., Smith, K., Midha, S., Ferreri, C. J., Dhakal, B., Dima, D., Costello, et al
2024
- **Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management after Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies.** *Transplantation and cellular therapy*
Shahid, Z., Jain, T., Dioverti, V., Pennisi, M., Mikkilineni, L., Kambhampati, S., Shah, N. N., Dadwal, S., Papanicolaou, G., Hamadani, M., Carpenter, P. A., Alfaro, G. M., Seo, et al
2024
- **Integrating Immune Therapies for the Treatment of Multiple Myeloma.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Mikkilineni, L., Sidana, S.
2023; 21 (12): 1303-1311
- **Early and Late Toxicities of Chimeric Antigen Receptor T-Cells.** *Hematology/oncology clinics of North America*
Epperly, R., Giordani, V. M., Mikkilineni, L., Shah, N. N.
2023
- **The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes.** *Blood advances*
Faruqi, A. J., Ligon, J. A., Borgman, P., Steinberg, S. M., Foley, T., Little, L., Mackall, C. L., Lee, D. W., Fry, T. J., Shalabi, H., Brudno, J., Yates, B., Mikkilineni, et al
2022; 6 (23): 6040-6050
- **Infectious Complications of CAR T-Cell Therapy Across Novel Antigen Targets in the first 30 days.** *Blood advances*
Mikkilineni, L., Yates, B., Steinberg, S. M., Shahani, S. A., Molina, J. C., Palmore, T. N., Lee, D. W., Kaplan, R. N., Mackall, C. L., Fry, T. J., Gea-Banacloche, J., Jerussi, T. D., Nussenblatt, et al
2021
- **Infectious Complications Associated with CAR T-Cell Therapy**
Mikkilineni, L., Shahani, S., Yates, B., Steinberg, S. M., Palmore, T., Nussenblatt, V., Lee, D. W., Kaplan, R. N., Mackall, C. L., Fry, T. J., Gea-Banacloche, J., Jerussi, T., Kochenderfer, et al
AMER SOC HEMATOLOGY.2019